FBXL15: A Potential Drug Target and Biomarker (G79176)

Target Name: FBXL15

NCBI ID: G79176

FBXL15

FBXL15: A Potential Drug Target and Biomarker

FBXL15, also known as pleckstrin and Sec7 domain protein, is a protein that is expressed in various tissues throughout the body. It plays a critical role in the regulation of cell signaling pathways, including the T-cell receptor signaling pathway. FBXL15 has also been shown to have potential as a drug target or biomarker.

The T-cell receptor signaling pathway is a critical pathway that regulates the development and function of T-cells, which play a crucial role in immune surveillance. The pathway is complex and involves multiple proteins, including FBXL15. FBXL15 is a protein that is expressed in various tissues throughout the body, including the brain, spleen, heart, and lymph nodes. It is highly conserved and has a calculated molecular weight of 180 kDa.

FBXL15 is a protein that is characterized by its pleckstrin and Sec7 domain. The pleckstrin domain is a regions of the protein that contain a unique sequence that is specific to FBXL15. It is the region that is involved in the interaction with the T-cell receptor. The Sec7 domain is a region of the protein that contains a unique sequence that is specific to FBXL15. It is the region that is involved in the interaction with the T-cell receptor.

FBXL15 has been shown to play a critical role in the regulation of the T-cell receptor signaling pathway. It is a negative regulator of the pathway, which means that it works to inhibit the activity of proteins that are involved in the pathway. FBXL15 is also known as pleckstrin and Sec7 domain protein because it is expressed in various tissues and has a unique sequence that is specific to it.

FBXL15 has been shown to have potential as a drug target. Several studies have shown that FBXL15 can be targeted with small molecules, such as inhibitors, to inhibit its activity in the T-cell receptor signaling pathway. These inhibitors have been shown to be effective in preclinical studies in treating various diseases, including cancer and autoimmune disorders.

FBXL15 has also been shown to be a potential biomarker for certain diseases. The T-cell receptor signaling pathway is involved in the regulation of many different diseases, including cancer, autoimmune disorders, and infections. Therefore, FBXL15 has the potential to be used as a biomarker for these diseases. Studies have shown that FBXL15 levels are elevated in certain diseases, such as cancer, and that inhibitors of the pathway have been shown to be effective in treating these diseases.

In conclusion, FBXL15 is a protein that is characterized by its unique pleckstrin and Sec7 domain and its role in the regulation of the T-cell receptor signaling pathway. It has the potential to be a drug target or biomarker for various diseases. Further research is needed to fully understand its function and potential as a drug.

Protein Name: F-box And Leucine Rich Repeat Protein 15

Functions: Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of SMURF1, thereby acting as a positive regulator of the BMP signaling pathway. Required for dorsal/ventral pattern formation and bone mass maintenance. Also mediates ubiquitination of SMURF2 and WWP2

The "FBXL15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXL15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets